Publications

BibTex format

@article{Ruscito:2017:10.1016/j.ejca.2017.04.016,
author = {Ruscito, I and Castillo-Tong, DC and Vergote, I and Ignat, I and Stanske, M and Vanderstichele, A and Ganapathi, RN and Glajzer, J and Kulbe, H and Trillsch, F and Mustea, A and Kreuzinger, C and Panici, PB and Gourley, C and Gabra, H and Kessler, M and Sehouli, J and Darb-Esfahani, S and Braicu, EI},
doi = {10.1016/j.ejca.2017.04.016},
journal = {European Journal of Cancer},
pages = {214--225},
title = {Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium},
url = {http://dx.doi.org/10.1016/j.ejca.2017.04.016},
volume = {79},
year = {2017}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundHigh-grade serous ovarian cancer (HGSOC) causes 80% of all ovarian cancer (OC) deaths. In this setting, the role of cancer stem-like cells (CSCs) is still unclear. In particular, the evolution of CSC biomarkers from primary (pOC) to recurrent (rOC) HGSOCs is unknown. Aim of this study was to investigate changes in CD133 and aldehyde dehydrogenase-1 (ALDH1) CSC biomarker expression in pOC and rOC HGSOCs.MethodsTwo-hundred and twenty-four pOC and rOC intrapatient paired tissue samples derived from 112 HGSOC patients were evaluated for CD133 and ALDH1 expression using immunohistochemistry (IHC); pOCs and rOCs were compared for CD133 and/or ALDH1 levels. Expression profiles were also correlated with patients' clinicopathological and survival data.ResultsSome 49.1% of the patient population (55/112) and 37.5% (42/112) pOCs were CD133+ and ALDH1+ respectively. CD133+ and ALDH1+ samples were detected in 33.9% (38/112) and 36.6% (41/112) rOCs. CD133/ALDH1 coexpression was observed in 23.2% (26/112) and 15.2% (17/112) of pOCs and rOCs respectively. Pairwise analysis showed a significant shift of CD133 staining from higher (pOCs) to lower expression levels (rOCs) (p < 0.0001). Furthermore, all CD133 + pOC patients were International Federation of Gynaecology and Obstetrics (FIGO)-stage III/IV (p < 0.0001) and had significantly worse progression-free interval (PFI) (p = 0.04) and overall survival (OS) (p = 0.02). On multivariate analysis, CD133/ALDH1 coexpression in pOCs was identified as independent prognostic factor for PFI (HR: 1.64; 95% CI: 1.03–2.60; p = 0.036) and OS (HR: 1.71; 95% CI: 1.01–2.88; p = 0.045). Analysis on 52 pts patients with known somatic BRCA status revealed that BRCA mutations did not influence CSC biomarker expression.ConclusionsThe study showed that CD133/ALDH1 expression impacts HGSOC patients' survival and first suggests that CSCs might undergo phenotypic change during the disease course similarly to non stem-like cancer
AU  - Ruscito,I
AU  - Castillo-Tong,DC
AU  - Vergote,I
AU  - Ignat,I
AU  - Stanske,M
AU  - Vanderstichele,A
AU  - Ganapathi,RN
AU  - Glajzer,J
AU  - Kulbe,H
AU  - Trillsch,F
AU  - Mustea,A
AU  - Kreuzinger,C
AU  - Panici,PB
AU  - Gourley,C
AU  - Gabra,H
AU  - Kessler,M
AU  - Sehouli,J
AU  - Darb-Esfahani,S
AU  - Braicu,EI
DO  - 10.1016/j.ejca.2017.04.016
EP  - 225
PY  - 2017///
SN  - 0959-8049
SP  - 214
TI  - Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
T2  - European Journal of Cancer
UR  - http://dx.doi.org/10.1016/j.ejca.2017.04.016
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000402872000024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/50572
VL  - 79
ER  -

Download

Professor Hani Gabra

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)